Risk of malignancy in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under immunosuppressive therapy: a single-center experience
- 23 June 2015
- journal article
- research article
- Published by Springer Nature in Internal and Emergency Medicine
- Vol. 11 (1) , 31-40
Abstract
Systemic inflammatory rheumatic diseases are associated with an increased risk of malignancy, in particular of lymphoproliferative disorders. Chronic inflammation, due to the disease itself, generates a microenvironment able to promote cancer development, but it is still controversial whether immunosuppressive therapy may contribute to carcinogenesis. The aim of the study was to evaluate the risk of malignancy in 399 patients affected by rheumatoid arthritis (RA), psoriatic arthritis and ankylosing spondylitis, all treated with either tumor necrosis factor α-inhibitors plus disease-modifying anti-rheumatic drugs (DMARDs) or DMARDs alone. The risk of malignancy in this cohort of patients, observed in the period between 2005 and 2011 at S. Andrea Hospital-Sapienza University of Rome, was compared with that of the general Italian population, matched for age, sex, and area of residence. Fourteen (3.5%) malignancies, five of which were hematologic, have been observed. The overall cancer risk was not significantly increased in comparison to the general population, whereas the risk of hematologic malignancies appeared significantly higher in RA patients (SIR 4.94, 95% CI 1.35-12.64), particularly in female gender (SIR 6.9, 0.95% CI 1.88-17.66). No significant association between therapy and malignancy was demonstrated in RA patients.Keywords
This publication has 55 references indexed in Scilit:
- Integrated safety in tocilizumab clinical trialsArthritis Research & Therapy, 2011
- Observational studies on the risk of cancer associated with tumor necrosis factor inhibitors in rheumatoid arthritis: A review of their methodologies and resultsArthritis & Rheumatism, 2011
- The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: A systematic review and meta-analysis of randomized controlled trialsJournal of the American Academy of Dermatology, 2011
- Non-AIDS Associated Kaposi's Sarcoma: Clinical Features and Treatment OutcomePLOS ONE, 2011
- Immunity, Inflammation, and CancerCell, 2010
- Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registryAnnals of the Rheumatic Diseases, 2010
- Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessmentAnnals of the Rheumatic Diseases, 2009
- Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and MalignanciesJAMA, 2006
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988
- Evaluation of Diagnostic Criteria for Ankylosing SpondylitisArthritis & Rheumatism, 1984